Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. New clinical abstract on SEL24(MEN1703) also available.
Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland
Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy